Ibogaine Dosage: What the Research Actually Shows
Ibogaine dosing stands out as poorly standardized. Decades of underground use and rising clinical interest have not led regulators to set official guidelines. Instead we rely on clinic protocols, case reports, and early research. This is what the data backs up.
Understanding the Ibogaine Flood Dose
The term "flood dose" refers to a full psychoactive dose of ibogaine intended to produce the complete visionary experience. This is the dose most commonly associated with treatment for opioid dependence and other substance use disorders.
A recent narrative review notes that ibogaine's initial rise in popularity during the 1960s came from reports by people with heroin addiction who claimed the substance stemmed their addiction (Moore et al., 2026). These reports involved what we now call flood doses, though standardized protocols did not exist at that time.
In practice, flood doses typically fall somewhere between 10 and 20 mg/kg of ibogaine hydrochloride, though this range comes from published clinic protocols and harm-reduction literature rather than from controlled dose-finding trials. Some providers set a lower internal ceiling, citing a higher rate of cardiac abnormalities above roughly 12 mg/kg. What clinics actually administer varies considerably based on the provider, the patient's health status, and the specific indication being treated.
Where people get stuck: assuming all flood doses are equivalent. They are not. Body weight calculations, alkaloid concentration in different preparations, and individual metabolism all affect the actual exposure.
The Pre Ibogaine Flood Dose Protocol
Most clinical settings use a test dose before administering a full flood dose. This smaller amount, typically given 12 to 24 hours before the main treatment, serves two purposes. First, it helps identify individuals who may have unusual sensitivity or allergic reactions to the compound. Second, it allows medical staff to observe cardiac responses under controlled conditions.
Test doses represent a fraction of the flood dose. Exact ratios vary by clinic. The principle is straightforward: expose the patient to enough ibogaine to reveal potential adverse reactions without triggering the full visionary state.
Recent regulatory developments in the United States have accelerated interest in formalizing these protocols. An Executive Order signed in April 2026 directed federal agencies to expedite development and review pathways for psychedelic and psychedelic-adjacent therapies, including ibogaine (Raffa et al., 2026). This regulatory momentum may eventually produce standardized dosing recommendations.
What Research Says About Ibogaine Microdosing
Ibogaine microdosing refers to taking sub-perceptual amounts of the compound, typically repeated over days or weeks. The theory is that smaller doses might provide some therapeutic benefit without the intense experience or medical risks of a flood dose.
Here is the honest assessment: clinical evidence specifically supporting ibogaine microdosing protocols is extremely limited. Most published research focuses on full therapeutic doses rather than microdosing regimens.
What we do know is that ibogaine has been classified among the psychoplastogens, compounds that rapidly promote neuroplasticity (Hoyer et al., 2026). Whether microdoses produce meaningful neuroplastic effects in humans has not been established through controlled trials.
Recent laboratory research has begun characterizing ibogaine's mechanism of action at the molecular level. One study demonstrated that ibogaine modulates multiple transporters at serotonin synapses (Hwu et al., 2026). However, this was conducted in cell models, and the clinical implications for microdosing remain speculative.
Ibogaine Dosage in Clinical Settings
The most rigorous dosing data comes from supervised clinical environments. A case report documented sustained abstinence in a 30-year-old male with severe ketamine use disorder following ibogaine treatment (Pérez Rosal et al., 2026). This patient had a five-year history of severe polysubstance dependence and underwent a structured 13-day residential program in Mexico, receiving an 800 mg ibogaine HCl flood dose (10.1 mg/kg), followed by two supplementary booster doses of 300 mg (3.8 mg/kg), all under continuous medical and ECG monitoring. That level of reported detail is unusual. Many published case reports omit the specific dose, the alkaloid form, or both.
Research with U.S. Special Operations veterans has examined a specific formulation combining ibogaine with magnesium supplementation before and after treatment. This approach was associated with rapid clinical improvements in veterans with traumatic brain injury and PTSD (Olash et al., 2026). Neuroimaging research in this population has also been conducted (Fonzo et al., 2026), though the abstract does not specify dosing details.
Psychedelic-assisted pharmacotherapy more broadly has gained recognition as a promising area of psychiatry, driven by unmet clinical needs in treatment-resistant mental disorders (Marazziti et al., 2026). Ibogaine falls within this emerging therapeutic category.
Why an Ibogaine Dosage Chart Is Difficult to Provide
You will find various ibogaine dosage charts online. Be cautious with them. Several factors make standardized charts problematic:
- Alkaloid content varies significantly between ibogaine hydrochloride, total alkaloid extracts, and raw root bark
- Individual metabolism differs based on genetics, liver function, and concurrent medications
- Cardiac risk factors require dose adjustments that no general chart can capture
- The indication being treated may influence optimal dosing
In practice, this looks like experienced practitioners adjusting doses based on multiple assessments rather than following a fixed chart. Medical screening, including cardiac evaluation, precedes any dosing decision in legitimate clinical settings.
Microdosing Ibogaine: Current Evidence Gaps
People interested in ibogaine microdosing protocol information should know that evidence gaps are substantial. No published controlled trials have established:
- Optimal microdose amounts
- Frequency of administration
- Duration of microdosing regimens
- Safety profile of repeated low-dose exposure
- Whether microdosing produces clinically meaningful effects
The assumption that microdosing carries minimal risk because the dose is small has not been validated. Ibogaine's effects on cardiac conduction may occur at doses below those producing psychoactive effects. Anyone considering microdosing should discuss this with a physician familiar with ibogaine's pharmacology.
Practical Considerations for Ibogaine Dose Selection
If you are researching ibogaine treatment, here is what matters most. Dose selection should never be separated from medical evaluation. Cardiac screening is essential regardless of the dose being considered. The setting matters as much as the dose. Unsupervised use at any dose level carries risks that supervised settings can mitigate.
Regulatory progress is accelerating. The FDA's prioritization of psychedelic therapies may eventually produce evidence-based dosing guidelines (Raffa et al., 2026). Until then, the most responsible approach involves working with experienced clinicians who can individualize treatment based on your specific medical situation.